36. Bonfield TL,Kavuru MS,Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol,2002,105:342-350.
[3]
37. Tagawa T,Yamasaki N,Tsuchiya T,et al. Living-donor lobar lung transplantation for pulmonary alveolar proteinosis in an adult:report of a case. Surg Today,2011,41:1142-1144.
[4]
38. Albores J,Seki A,Fishbein MC,et al. A rare occurrence of pulmonary alveolar proteinosis after lung transplantation. Semin Respir Crit Care Med,2013,34:431-438.
[5]
40. Khan A,Agarwal R. Pulmonary alveolar proteinosis.Respir Care,2011,56:1016-1028.
3. Shah PL,Hansell D,Lawson PR,et al. Pulmonary alveolar proteinosis:clinical aspects and current concepts on pathogenesis. Thorax,2000,55:67-77.
[10]
4. Carey B,Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol,2010,135:223-235.
[11]
5. Khan A,Agarwal R,Aggarwal AN. Effectiveness of granulocyte-macrophage colony-stimulating factor therapy in autoimmune pulmonary alveolar proteinosis:a meta-analysis of observational studies. Chest,2012,141:1273-1283.
[12]
6. Kavuru MS,Malur A,Marshall I,et al. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J,2011,38:1361-1367.
[13]
7. Luisetti M,Rodi G,Perotti C,et al. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J,2009,33:1220-1222.
[14]
8. Verhasselt-Crinquette M,Franquet-Ansart H,Rakza T,et al. Congenital pulmonary alveolar proteinosis related to a surfactant protein B deficiency:report of two cases. Ann Pathol,2009,29:481-484.
[15]
17. Inoue Y,Trapnell BC,Tazawa R,et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med,2008,177:752-762.
[16]
19. Campo I,Mariani F,Rodi G,et al. Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet J Rare Dis,2013,8:40.
[17]
20. Ramirez J,Kieffer RF,Ball WC Jr. Bronchopulmonary lavage in man. Ann Intern Med,1965,63:819-828.
22. Prakash UB,Barham SS,Carpenter HA,et al. Pulmonary alveolar phospholipoproteinosis:experience with 34 cases and review. Mayo Clin Proc,1987,62:499-518.
[20]
24. Seymour JF,Dunn AR,Vincent JM,et al. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med,1996,335:1924-1925.
[21]
25. Kavuru MS,Sullivan EJ,Piccin R,et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med,2000,161:1143-1148.
[22]
26. Seymour JF,Presneill JJ,Schoch OD,et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med,2001,163:524-531.
[23]
27. Venkateshiah SB,Yan TD,Bonfield TL,et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest,2006,130:227-237.
[24]
28. Reed JA,Ikegami M,Cianciolo ER,et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol,1999,276:L556-563.
[25]
29. Tazawa R,Hamano E,Arai T,et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med,2005,171:1142-1149.
34. Amital A,Dux S,Shitrit D, et al. Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis. Thorax,2010,65:1025-1026.
9. Griese M,Ripper J,Sibbersen A,et al. Long-term follow-up and treatment of congenital alveolar proteinosis. BMC Pediatr,2011,11:72.
[33]
10. Dranoff G,Crawford AD,Sadelain M,et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science,1994,264:713-716.
[34]
11. Stanley E,Lieschke GJ,Grail D,et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA,1994,91:5592-5596.
[35]
12. Shibata Y,Berclaz PY,Chroneos ZC,et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity,2001,15:557-567.
[36]
13. Sakagami T,Uchida K,Suzuki T,et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med,2009,361:2679-2681.
[37]
14. Uchida K,Nakata K,Trapnell BC,et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colonystimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood,2004,103:1089-1098.
[38]
15. Sakagami T,Beck D,Uchida K,et al. Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med,2010,182:49-61.
[39]
16. Ben-Dov I,Segel MJ. Autoimmune pulmonary alveolar proteinosis:clinical course and diagnostic criteria. Autoimmun Rev,2014,13:513-517.
[40]
18. Bonella F,Bauer PC,Griese M,et al. Pulmonary alveolar proteinosis:new insights from a single-center cohort of 70 patients. Respir Med,2011,105:1908-1916.
[41]
23. Hasan N,Bagga S,Monteagudo J,et al. Extracorporeal membrane oxygenation to support whole-lung lavage in pulmonary alveolar proteinosis:salvage of the drowned lungs. J Bronchology Interv Pulmonol,2013,20:41-44.
[42]
39. Huddleston CB,Bloch JB,Sweet SC,et al. Lung transplantation in children. Ann Surg,2002,236:270-276.
